Final NHS green light for Allergan’s IBS-D drug

Allergan’s Truberzi has become the first treatment for irritable bowel syndrome with diarrhoea (IBS-D) to be reviewed and recommended by the National Institute for Health and Care Excellence for use on the NHS in England and Wales. Final guidelines published by the Institute have backed the drug for patients who have not responded to or cannot take other treatments, and recommend that the therapy be initiated in hospital. Truberzi (eluxadoline) is a first-in-class, oral drug that works by binding to receptors in the digestive system to slow down the movement of food through the gut.